BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23954809)

  • 1. A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro.
    Zhu X; Tao K; Li Y; Li S; Zhang L; Wang D; Zhong L; Feng W
    Immunol Lett; 2013; 154(1-2):18-24. PubMed ID: 23954809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
    Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
    Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
    Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
    Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
    Barth S; Huhn M; Wels W; Diehl V; Engert A
    Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
    Barth S; Matthey B; Huhn M; Diehl V; Engert A
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
    Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
    Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld JC; Tesch H; Bohlen H; Diehl V; Engert A
    Cytokines Mol Ther; 1996 Sep; 2(3):139-46. PubMed ID: 9384698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
    Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
    J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
    Matthey B; Engert A; Klimka A; Diehl V; Barth S
    Gene; 1999 Mar; 229(1-2):145-53. PubMed ID: 10095114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.
    Tur MK; Sasse S; Stöcker M; Djabelkhir K; Huhn M; Matthey B; Gottstein C; Pfitzner T; Engert A; Barth S
    Int J Mol Med; 2001 Nov; 8(5):579-84. PubMed ID: 11605031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
    Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
    MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
    Schwenkert M; Birkholz K; Schwemmlein M; Kellner C; Kügler M; Peipp M; Nettelbeck DM; Schuler-Thurner B; Schaft N; Dörrie J; Ferrone S; Kämpgen E; Fey GH
    Melanoma Res; 2008 Apr; 18(2):73-84. PubMed ID: 18337643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.
    Mladenov R; Hristodorov D; Cremer C; Hein L; Kreutzer F; Stroisch T; Niesen J; Brehm H; Blume T; Brümmendorf TH; Jost E; Thepen T; Fischer R; Stockmeyer B; Barth S; Stein C
    Int J Cancer; 2015 Dec; 137(11):2729-38. PubMed ID: 26041304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
    Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
    Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
    Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Target-specific cytotoxic activity of recombinant fusion toxin C-CPE-ETA' against CLDN-3,4-overexpressing ovarian cancer cells].
    Yao Q; Zheng QM; Wen JF; Lü T; Wei MQ; Dai SZ
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):897-902. PubMed ID: 21223796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
    Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
    Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Soluble expression of recombinant immunotoxin against human bladder carcinoma and its anti-tumor activity].
    Chao K; He D; Yang H; Zhang Z; Lin Q; Guo AG; Huang HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):568-71. PubMed ID: 15367349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
    Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.